Table 4.
Model-coefficients of predictor variable of the linear multivariate regression model with ΔCIMT as outcome variable (BMI was excluded because of high-correlation with Waist)
| 95% CI | p-value | ||
|---|---|---|---|
| Waist circumference (Baseline) |
0.19 |
(-0.05 to 0.44) |
0.12 |
| HDL-cholesterol (Baseline) |
0.10 |
(-0.26 to 0.46) |
0.56 |
| Triglycerides (Baseline) |
-0.02 |
(-0.06 to 0.02) |
0.33 |
| Serum creatinine (Baseline) |
-1.32 |
(-15.08 to 12.45) |
0.85 |
| Smoking (Baseline) |
-4.15 |
(-12.53 to 4.22) |
0.32 |
| Blood glucose 2h (Baseline) |
0.00 |
(-0.04 to 0.04) |
0.98 |
| CHD risk score (Baseline) |
-0.25 |
(-0.76 to 0.26) |
0.33 |
| PROCAM risk score (Baseline) |
0.20 |
(-0.21to 0.6) |
0.34 |
| Statin therapy (Baseline) |
-3.95 |
(-10.78 to 2.87) |
0.25 |
| CIMT (Baseline) |
-11.29 |
(-37.99 to 15.4) |
0.40 |
| Δ HDL-cholesterol |
-0.02 |
(-0.15to 0.12) |
0.82 |
| Δ Triglycerides |
0.00 |
(-0.05 to 0.05) |
0.99 |
| Δ NTproBNP |
-0.02 |
(-0.04 to 0) |
0.09 |
| Δ Blood glucose 2h |
0.04 |
(-0.11 to 0.2) |
0.58 |
| Sex |
-1.30 |
(-11.66 to9.06) |
0.80 |
| Age (Baseline) |
0.02 |
(-0.69 to 0.72) |
0.96 |
| Statin therapy (3 Months) | -3.86 | (-10.8 to 3.08) | 0.27 |
CHD = Coronary Heart Disease (UKPDS risk engine 2.0); PROCAM – Prospective Cardiovascular Münster; IMT – Intima Media Thickness; NTproBNP = N-terminal Pro B-Type Natriuretic Peptide; = estimates of beta coefficient; CI = confidence interval.
Male gender, statin therapy and smoking were assigned a value of 1. Female gender, no statin therapy and non-smoking were assigned a value of 0.